Heron Therapeutics Inc. (HRTX)
NASDAQ: HRTX
· Real-Time Price · USD
1.21
-0.01 (-0.41%)
At close: Sep 26, 2025, 3:59 PM
1.21
0.00%
After-hours: Sep 26, 2025, 07:34 PM EDT
Heron Therapeutics Revenue Breakdown
| Period Ending | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| C I N V A N T I Revenue | 24.14M | 25.74M | 51.8M | 22.66M | 24.93M | 25.62M | 47.54M | 24.47M | 22.86M | 23.07M | 21.17M | 22.66M | 20.3M | 17.31M | 18M | 19.7M | 18.5M | 20.2M | 19.8M | 22.6M | 25.2M | 34.6M | 36.4M |
| C I N V A N T I Revenue Growth | -6.21% | -50.31% | +128.58% | -9.09% | -2.69% | -46.11% | +94.25% | +7.08% | -0.94% | +8.99% | -6.58% | +11.63% | +17.29% | -3.85% | -8.63% | +6.49% | -8.42% | +2.02% | -12.39% | -10.32% | -27.17% | -4.95% | n/a |
| S U S T O L Revenue | 2.4M | 2.86M | 7.76M | 2.76M | 4.25M | 3.62M | 7.24M | 2.84M | 2.98M | 3.05M | 2.67M | 2.45M | 2.1M | 2.52M | 3.1M | 2.7M | 1.5M | 400K | 200K | 100K | 200K | 500K | 6.2M |
| S U S T O L Revenue Growth | -15.91% | -63.18% | +181.00% | -34.93% | +17.46% | -50.06% | +155.22% | -4.93% | -2.26% | +14.26% | +9.20% | +16.48% | -16.50% | -18.87% | +14.81% | +80.00% | +275.00% | +100.00% | +100.00% | -50.00% | -60.00% | -91.94% | n/a |
| Z Y N R E L E F Revenue | 8.19M | 8.04M | 14.29M | 6.25M | 5.83M | 5.01M | 10.07M | 4.13M | 3.53M | 3.9M | 2.72M | 2.52M | 1.1M | 824K | 2.1M | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Z Y N R E L E F Revenue Growth | +1.83% | -43.72% | +128.79% | +7.10% | +16.32% | -50.20% | +143.85% | +16.84% | -9.50% | +43.69% | +7.69% | +129.36% | +33.50% | -60.76% | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Operating Expense Breakdown
| Period Ending | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | Dec 31, 2018 | Sep 30, 2018 | Jun 30, 2018 | Mar 31, 2018 | Dec 31, 2017 | Sep 30, 2017 | Jun 30, 2017 | Mar 31, 2017 | Dec 31, 2016 | Sep 30, 2016 | Jun 30, 2016 | Mar 31, 2016 | Dec 31, 2015 | Sep 30, 2015 | Jun 30, 2015 | Mar 31, 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selling, General, and Administrative Revenue | 26.05M | 25.01M | 23.2M | 23.34M | 27.52M | 26.42M | 23.62M | 24.6M | 36.44M | 32.01M | 26.7M | 28.18M | 32.12M | 32.95M | 34.37M | 34.99M | 33.16M | 24.81M | 28.06M | 22M | 25.41M | 30.62M | 30.29M | 25.57M | 33.42M | 38.37M | 28.7M | 23.57M | 20.74M | 20.86M | 22.85M | 19.99M | 20.95M | 18.36M | 18.54M | 17.49M | 15.78M | 17.22M | 14.8M | 8.25M | 6.84M | 5.86M |
| Selling, General, and Administrative Revenue Growth | +4.13% | +7.81% | -0.61% | -15.17% | +4.18% | +11.85% | -3.98% | -32.49% | +13.83% | +19.88% | -5.25% | -12.27% | -2.54% | -4.13% | -1.77% | +5.53% | +33.65% | -11.57% | +27.54% | -13.42% | -17.02% | +1.07% | +18.46% | -23.49% | -12.88% | +33.71% | +21.75% | +13.64% | -0.59% | -8.69% | +14.29% | -4.60% | +14.13% | -0.98% | +6.00% | +10.85% | -8.36% | +16.37% | +79.36% | +20.63% | +16.79% | n/a |
| Research and Development Revenue | 2.93M | 2.28M | 3.18M | 4.46M | 4.43M | 4.61M | 10.95M | 13.56M | 17.57M | 13.82M | 11.06M | 25.55M | 28.83M | 42.07M | 28.88M | 28.59M | 35.23M | 38.12M | 44.45M | 49.18M | 44M | 36.89M | 48.28M | 34.71M | 41.42M | 42.97M | 39.89M | 30.42M | 30.16M | 39.56M | 47.76M | 28.84M | 28.6M | 33.38M | 29.5M | 30.24M | 27.29M | 16.09M | 16.26M | 14.24M | 16.18M | 14.5M |
| Research and Development Revenue Growth | +28.74% | -28.29% | -28.82% | +0.74% | -3.82% | -57.92% | -19.24% | -22.84% | +27.18% | +24.96% | -56.72% | -11.41% | -31.46% | +45.69% | +0.99% | -18.84% | -7.56% | -14.26% | -9.62% | +11.77% | +19.27% | -23.58% | +39.09% | -16.21% | -3.60% | +7.72% | +31.13% | +0.87% | -23.77% | -17.16% | +65.57% | +0.86% | -14.34% | +13.15% | -2.44% | +10.83% | +69.56% | -1.05% | +14.20% | -11.96% | +11.52% | n/a |
| Sales and Marketing Revenue | 11.57M | 12.31M | 11.06M | 10.97M | 13.61M | 11.44M | 12.33M | 12.96M | 21.2M | 21.15M | 17.77M | 18.38M | 22.94M | 23.42M | 24.49M | 25.21M | 22.25M | 15.24M | 15.55M | 12.52M | 15.59M | 20.2M | 20.42M | 16.98M | 23.65M | 28.72M | 19.96M | 16.28M | 14.53M | 13.84M | 16.68M | 13.53M | 14.77M | 11.62M | 12.65M | 12.16M | 11.01M | 11.85M | 8.2M | n/a | n/a | n/a |
| Sales and Marketing Revenue Growth | -5.98% | +11.34% | +0.77% | -19.41% | +18.98% | -7.19% | -4.85% | -38.90% | +0.24% | +19.01% | -3.28% | -19.88% | -2.07% | -4.35% | -2.85% | +13.29% | +46.04% | -2.04% | +24.27% | -19.72% | -22.81% | -1.10% | +20.28% | -28.21% | -17.66% | +43.91% | +22.58% | +12.04% | +5.03% | -17.07% | +23.31% | -8.40% | +27.12% | -8.15% | +4.04% | +10.48% | -7.15% | +44.58% | n/a | n/a | n/a | n/a |